Celgene has had disappointing sales and trials of new drugs recently, while its blockbuster cancer fighter Revlimid faces challenges. Celgene cut its full-year outlook in late October, sending shares plunging. The stock has risen somewhat since then, but only in line with the S&P 500 index.